Advanced pancreatic cancer
Conditions
Interventions
control group:Placebo + chemotherapy
trial group:Organic selenium + chemotherapy
Sponsors
Beijing Hospital of Traditional Chinese Medicine,Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with diagnosed III-IV pancreatic cancer; 2. Have measurable or evaluable lesions on imaging, or have evaluable clinical observation indicators, such as abdominal pain and/or low back pain, loss of appetite, weight loss (and before the disease) Relative reduction>15%) etc.; 3. Serum selenium = 60 points; 5. Aged 18-75 years; 6. Estimated survival time>3 months; 7. New treatment or discontinuation of other anticancer treatments 4 Weeks or more; 8. Patients and their family members are aware of the treatment plan of this study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, liver, lung, and kidney damage; 2. Patients with mental illness; 3. Patients with hematological diseases; 4. Patients who have recently had immunosuppressants and participated in other experimental treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical benefit response;Effective treatment;Tumor marker changes; | — |
Countries
China
Contacts
Public ContactQing Zhang
Beijing Hospital of Traditional Chinese Medicine,Capital Medical University
Outcome results
None listed